ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
35.58
0.14%
US Tech 100
17,618.80
0.05%
S&P 500
5,187.70
0.13%
US Dollar vs CAD
1.37565
0.17%
Bitcoin
62,683.23
0.56%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. Europe
  5. EU
  6. Hyloris Pharmaceuticals SA (HYL)

  7. Hyloris Pharmaceuticals SA (HYL) News

HYL

Hyloris Pharmaceuticals (HYL)

Hyloris Pharmaceuticals SA
Date:
Sort by:
 Showing the most relevant articles for your search:EU:HYL
DateTimeSourceHeadlineSymbolCompany
03/14/20241:00AMGlobeNewswire Inc.Hyloris Présente ses Résultats Annuels pour 2023 et ses PerspectivesEU:HYLHyloris Pharmaceuticals SA
03/14/20241:00AMGlobeNewswire Inc.Hyloris Reports Full Year Results for 2023 & Provides Business OutlookEU:HYLHyloris Pharmaceuticals SA
03/14/202412:59AMGlobeNewswire Inc.Communication at the request of the FSMA on the transactions with QliniqEU:HYLHyloris Pharmaceuticals SA
03/14/202412:59AMGlobeNewswire Inc.Communiqué à la requête de la FSMA sur les transactions avec QliniQEU:HYLHyloris Pharmaceuticals SA
03/08/202412:00AMGlobeNewswire Inc.Hyloris Annonce ses Résultats Financiers Annuels le 14 mars 2024EU:HYLHyloris Pharmaceuticals SA
03/08/202412:00AMGlobeNewswire Inc.Hyloris to Report 2023 Full-Year Results on 14 March 2024EU:HYLHyloris Pharmaceuticals SA
03/08/202412:00AMGlobeNewswire Inc.Hyloris to Report 2023 Full-Year Results on 14 March 2024EU:HYLHyloris Pharmaceuticals SA
02/27/202411:00AMGlobeNewswire Inc.Hyloris Annonce le Lancement de Maxigesic® IV aux Etats-Unis ainsi que son Approbation au CanadaEU:HYLHyloris Pharmaceuticals SA
02/27/202411:00AMGlobeNewswire Inc.Hyloris Announces Launch of Maxigesic® IV in the U.S. and approval In CanadaEU:HYLHyloris Pharmaceuticals SA
02/14/202411:00AMGlobeNewswire Inc.Hyloris Enrolls First Patient in Phase 3 Clinical Trial for its Proprietary Mouth Rinse to Control Incidences of Bleeding Related to Dental ProceduresEU:HYLHyloris Pharmaceuticals SA
02/14/202411:00AMGlobeNewswire Inc.Hyloris Recrute un Premier Patient dans le Cadre d'un Essai Clinique de Phase 3 portant sur son Rince-Bouche Breveté Destiné à Contrôler les Saignements lors des Interventions DentairesEU:HYLHyloris Pharmaceuticals SA
01/30/202412:00AMGlobeNewswire Inc.Hyloris and Purna Female Healthcare Announce Positive Results from Phase 2 Trial in Patients with Acute Vulvovaginal Candidiasis (VVC)EU:HYLHyloris Pharmaceuticals SA
01/30/202412:00AMGlobeNewswire Inc.Hyloris et Purna Female Healthcare Annoncent des Résultats Positifs de leur Essai Clinique de Phase 2 chez des Patientes atteintes de Candidose Vulvovaginale Aiguë (CVV)EU:HYLHyloris Pharmaceuticals SA
01/18/202412:00PMGlobeNewswire Inc.Hyloris Broadens Pipeline with new Product Candidate for Vulvar Lichen Sclerosus (VLS)EU:HYLHyloris Pharmaceuticals SA
01/18/202412:00PMGlobeNewswire Inc.Hyloris Elargit son Portefeuille de Produits avec un Nouveau Produit Candidat pour le Lichen Scléreux Vulvaire (LSV)EU:HYLHyloris Pharmaceuticals SA
01/16/202412:30PMGlobeNewswire Inc.Orphan Drug Designation Granted to PTX-252 by U.S. FDA for the Treatment of Acute Myeloid Leukaemia (AML)EU:HYLHyloris Pharmaceuticals SA
01/16/202412:30PMGlobeNewswire Inc.La FDA Américaine Accorde la Qualification de Médicament Orphelin au PTX-252 pour le Traitement de la Leucémie Myéloïde Aiguë (LMA)EU:HYLHyloris Pharmaceuticals SA
01/16/202412:30PMGlobeNewswire Inc.Orphan Drug Designation Granted to PTX-252 by U.S. FDA for the Treatment of Acute Myeloid Leukaemia (AML)EU:HYLHyloris Pharmaceuticals SA
01/16/202410:30AMGlobeNewswire Inc.Pleco Therapeutics receives FDA Orphan Drug DesignationEU:HYLHyloris Pharmaceuticals SA
12/26/202311:00AMGlobeNewswire Inc.Hyloris Annonce des Résultats Cliniques Positifs pour son Produit Valacyclovir (HY-029) en suspension oraleEU:HYLHyloris Pharmaceuticals SA
12/21/202311:30AMGlobeNewswire Inc.Hyloris Broadens Pipeline with new Product Candidate in Burning Mouth SyndromeEU:HYLHyloris Pharmaceuticals SA
12/21/202311:30AMGlobeNewswire Inc.Hyloris Broadens Pipeline with new Product Candidate in Burning Mouth SyndromeEU:HYLHyloris Pharmaceuticals SA
12/21/202311:30AMGlobeNewswire Inc.Hyloris élargit son Portefeuille avec un Nouveau Produit Candidat pour le Syndrome de la Bouche BrûlanteEU:HYLHyloris Pharmaceuticals SA
12/04/202312:00AMGlobeNewswire Inc.Hyloris announces US FDA approval for Podofilox GelEU:HYLHyloris Pharmaceuticals SA
12/04/202312:00AMGlobeNewswire Inc.Hyloris announces US FDA approval for Podofilox GelEU:HYLHyloris Pharmaceuticals SA
12/04/202312:00AMGlobeNewswire Inc.Hyloris annonce l'approbation du Gel Podofilox par la FDA américaineEU:HYLHyloris Pharmaceuticals SA
10/24/202312:00AMGlobeNewswire Inc.Hyloris Announces Out-Licensing of Atomoxetine Oral Liquid in CanadaEU:HYLHyloris Pharmaceuticals SA
10/24/202312:00AMGlobeNewswire Inc.Hyloris annonce un accord de licence pour l'Atomoxetine Oral Liquide au CanadaEU:HYLHyloris Pharmaceuticals SA
10/24/202312:00AMGlobeNewswire Inc.Hyloris Announces Out-Licensing of Atomoxetine Oral Liquid in CanadaEU:HYLHyloris Pharmaceuticals SA
09/06/20233:00PMGlobeNewswire Inc.Hyloris Pharmaceuticals Reports 2023 Half-Year Results and provides Business OutlookEU:HYLHyloris Pharmaceuticals SA
 Showing the most relevant articles for your search:EU:HYL

Your Recent History

USOTC
MONI
Moon Equity (PK)
USOTC
GSTC
Globestar Therapeutics (PK)
USOTC
INKW
Greene Concepts (PK)
USOTC
WDLF
Decentral Life (PK)
NASDAQ
HOLO
MicroCloud Hologram
USOTC
TSOI
Therapeutic Solutions (PK)
USOTC
RXMD
Progressive Care (QB)
USOTC
HMBL
HUMBL (PK)
USOTC
AXXA
Exxe (PK)
USOTC
IQST
iQSTEL (QX)
USOTC
CLNV
Clean Vision (QB)
USOTC
CYDY
CytoDyn (QB)
NASDAQ
FCEL
FuelCell Energy
NYSE
GME
GameStop
USOTC
DBMM
Digital Brand Media and ... (PK)
USOTC
TPTW
TPT Global Tech (CE)
Delayed Upgrade Clock
ADVFN Logo

Canada
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved